Oncotarget 2017 May 7. Epub 2017 May 7.
The Jenner Institute, University of Oxford, Roosevelt Drive Oxford, OX3 7DQ, United Kingdom.
The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent. In the present study, we have evaluated a heterologous prime boost regime based on the simian adenovirus ChAdOx1 and modified vaccinia virus Ankara (MVA) expressing 5T4 for immunogenicity and tumour protective efficacy in a mouse cancer model. Read More